Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Park, S.-H.
Right arrow Articles by Yoo, Y. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, S.-H.
Right arrow Articles by Yoo, Y. D.
Clinical Cancer Research Vol. 6, 4915-4920, December 2000
© 2000 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Antisense of Human Peroxiredoxin II Enhances Radiation-induced Cell Death1

Sun-Hee Park2,3, Young Min Chung2, Yong-Sik Lee, Hyung Jung Kim, Jun Suk Kim, Ho Zoon Chae and Young Do Yoo4

Laboratory of Experimental Therapeutics [S-H. P., Y. M. C., Y. D. Y.] and Department of Otolaryngology [Y-S. L.], Korea Cancer Center Hospital, Seoul 139-706; Department of Internal Medicine, Yonsei University College of Medicine, Seoul 135-720 [H. J. K.]; Department of Internal Medicine, Korea University Guro Hospital, Seoul 152-050 [J. S. K.]; and Department of Biology, Chonnam National University, Kwangju 500-757 [H. Z. C.], Korea

Human peroxiredoxin II (Prx II) has been known to function as an antioxidant enzyme in cells. Using head-and-neck cancer cell lines, we investigated whether Prx II expression is related to the resistance of cells to radiation therapy in vivo and in vitro, and whether a Prx II antisense serves as a radiosensitizer. Increased expression of Prx II was observed in tissues isolated from the patients who did not respond to radiation therapy, whereas Prx II expression was weak in tissues from the patients with regressed tumors. Enhanced expression of Prx II in UMSCC-11A (11A) cells was also observed after treatment with {gamma} radiation. This increased expression conferred radiation resistance to cancer cells because overexpression of Prx II protected 11A cells from radiation-induced cell death, suggesting that blocking Prx II expression could enhance radiation sensitivity. Treatment of 11A cells with a Prx II antisense decreased induction of Prx II, enhancing the radiation sensitivity. From these results, we suggest that stress-induced overexpression of Prx II increases radiation resistance via protection of cancer cells from radiation-induced oxidative cytolysis and that a Prx II antisense can be used as a radiosensitizer.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
J.-H. Kim, P. N. Bogner, S.-H. Baek, N. Ramnath, P. Liang, H.-R. Kim, C. Andrews, and Y.-M. Park
Up-Regulation of Peroxiredoxin 1 in Lung Cancer and Its Implication as a Prognostic and Therapeutic Target
Clin. Cancer Res., April 15, 2008; 14(8): 2326 - 2333.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Iraqui, G. Faye, S. Ragu, A. Masurel-Heneman, R. D. Kolodner, and M.-E. Huang
Human Peroxiredoxin PrxI Is an Orthologue of Yeast Tsa1, Capable of Suppressing Genome Instability in Saccharomyces cerevisiae
Cancer Res., February 15, 2008; 68(4): 1055 - 1063.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Lee, K.-S. Choi, J. Riddell, C. Ip, D. Ghosh, J.-H. Park, and Y.-M. Park
Human Peroxiredoxin 1 and 2 Are Not Duplicate Proteins: THE UNIQUE PRESENCE OF CYS83 IN Prx1 UNDERSCORES THE STRUCTURAL AND FUNCTIONAL DIFFERENCES BETWEEN Prx1 AND Prx2
J. Biol. Chem., July 27, 2007; 282(30): 22011 - 22022.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
G. Monteiro, B. B. Horta, D. C. Pimenta, O. Augusto, and L. E. S. Netto
Reduction of 1-Cys peroxiredoxins by ascorbate changes the thiol-specific antioxidant paradigm, revealing another function of vitamin C
PNAS, March 20, 2007; 104(12): 4886 - 4891.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Okamoto, J. Li, A. O. Vortmeyer, H. Jaffe, Y.-S. Lee, S. Glasker, T.-S. Sohn, W. Zeng, B. Ikejiri, M. A. Proescholdt, et al.
Comparative proteomic profiles of meningioma subtypes.
Cancer Res., October 15, 2006; 66(20): 10199 - 10204.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Wang, D. Tamae, T. LeBon, J. E. Shively, Y. Yen, and J. J. Li
The Role of Peroxiredoxin II in Radiation-Resistant MCF-7 Breast Cancer Cells
Cancer Res., November 15, 2005; 65(22): 10338 - 10346.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
Z. A. Wood, L. B. Poole, and P. A. Karplus
Peroxiredoxin Evolution and the Regulation of Hydrogen Peroxide Signaling
Science, April 25, 2003; 300(5619): 650 - 653.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
C. Yang, D. A. Maiguel, and F. Carrier
Identification of nucleolin and nucleophosmin as genotoxic stress-responsive RNA-binding proteins
Nucleic Acids Res., May 15, 2002; 30(10): 2251 - 2260.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.